Cerebro NeuroTech


Developer of AI and spatial computing software for early detection and assessment of neurocognitive disease, focused on rapid detection of traumatic brain injury (TBI). The technology is in a research/beta testing phase and is explicitly not FDA-cleared for commercial distribution; intended for research use only.

Industries

artificial-intelligence
health-care
health-diagnostics
software

Nr. of Employees

small (1-50)

Cerebro NeuroTech

Birmingham, Alabama, United States, North America


Products

Rapid detection software for traumatic brain injury (research use)

An AI- and spatial-computing-based software intended to rapidly detect signs of traumatic brain injury for research and early-assessment workflows. Not cleared for commercial clinical use in the U.S.

AI/ML neural network research device

Research-stage neural network system developed for neurocognitive disease detection and algorithm development; explicitly labeled for research use only and not FDA-cleared.


Services

Beta testing and research collaborations

Program to enroll research users for evaluation and iterative development of research-use diagnostic software and devices.

Expertise Areas

  • Digital health diagnostics
  • AI/ML for medical imaging and assessment
  • Traumatic brain injury detection
  • Neurocognitive disease assessment
  • Show More (1)

Key Technologies

  • Machine learning neural networks
  • Spatial computing
  • AI-driven diagnostics
  • Digital health software platforms

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.